Inve India ▾
OSOSELDEVICE

OSEL Devices Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 2 Jun 2026

OSEL Devices reported a strong H2 FY26, with significant growth in revenue, EBITDA, and PAT, driven by all three business verticals. The company is strategically expanding its export capabilities with the upcoming JNPA SEZ hub and enhancing its hearing aid segment through the SFL retail acquisition for higher margins. However, the period saw a doubling of interest costs and some revenue deferrals due to logistics issues, alongside a reclassification of prior financial statements.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

What they filed

Q4 FY26: revenue up 78.0%, net profit up 75.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY24Q4 FY24Q2 FY25Q4 FY25Q2 FY26Q4 FY26
Revenue51 82 87 99 147 +188%146 +78%
EBITDA9 14 13 20 25 +178%29 +107%
Net profit5 8 8 12 15 +200%14 +75%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.